Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for rare diseases with significant unmet medical needs. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on conditions driven by bradykinin-mediated pathways, most notably hereditary angioedema (HAE). Pharvaris does not currently generate commercial revenue and remains focused on research and development activities.
The company’s core strategy centers on developing small-molecule, orally administered drugs intended to improve upon existing injectable or infusion-based therapies. Pharvaris was founded in 2015 and is headquartered in the Netherlands. It became publicly traded on Nasdaq under the ticker PHVS following an initial public offering in 2021, positioning itself as one of the few companies pursuing oral prophylactic and on-demand treatments in the HAE market.
Business Operations
Pharvaris operates as a single-segment biotechnology company focused on drug discovery and clinical development. Its primary business activity is the development of deucrictibant (also referred to as PHVS416), an oral, selective bradykinin B2 receptor antagonist being evaluated for both on-demand and prophylactic treatment of HAE. Research and development expenses represent the vast majority of operating costs.
Operations are conducted through the parent company, Pharvaris N.V., and its wholly owned subsidiaries, including Pharvaris Netherlands B.V. and Pharvaris USA, Inc., which support European and U.S.-based clinical, regulatory, and administrative activities. The company relies on third-party contract research organizations and manufacturing partners for clinical trials and drug production rather than owning manufacturing facilities.
Strategic Position & Investments
Pharvaris’ strategic direction is centered on advancing deucrictibant through late-stage clinical development and, if successful, toward regulatory approval. The company’s investment priorities are focused on expanding clinical trial programs, strengthening regulatory engagement, and exploring lifecycle opportunities for its bradykinin B2 receptor antagonist platform in additional indications beyond HAE.
To date, Pharvaris has not completed any material acquisitions and does not maintain a diversified portfolio of marketed or revenue-generating assets. Its strategic positioning is defined by its focus on oral delivery, which the company believes could offer meaningful differentiation compared with existing injectable therapies. Public disclosures do not indicate significant equity investments or joint ventures; data on additional pipeline assets beyond deucrictibant is limited and inconclusive based on available public sources.
Geographic Footprint
Pharvaris is headquartered in Leiden, the Netherlands, with additional corporate and clinical operations in the United States. Its geographic presence reflects its focus on conducting multinational clinical trials and engaging with regulators in major pharmaceutical markets.
Clinical development activities span North America and Europe, corresponding to regions with established HAE treatment infrastructure and patient populations. While the company does not have commercial operations, its global footprint is designed to support future regulatory submissions and potential commercialization in major international markets.
Leadership & Governance
Pharvaris is led by an executive team with experience in rare diseases, pharmaceutical development, and global drug commercialization. The company is governed by a board of directors consistent with Dutch corporate governance standards and U.S. public company requirements following its Nasdaq listing.
Key executives include:
- Berndt Modig – Chief Executive Officer
- Karin de Wit – Chief Financial Officer
- Elisabeth Björk – Chief Medical Officer
- Hans R. Schikan – Chairman of the Board
The leadership team’s stated strategic vision emphasizes disciplined clinical execution, patient-centric drug design, and building long-term value through focused development of differentiated oral therapies for rare diseases.